On May 10, 2021, Biogen Inc. and Capsigen Inc. announced they have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to deliver transformative gene therapies that address the underlying genetic causes of various CNS and neuromuscular disorders. Wilson Sonsini Goodrich & Rosati advised Capsigen on IP matters related to the collaboration.

As a part of the collaboration, Capsigen’s proprietary TRADE™ platform and associated technologies will be utilized with the aim to create and identify novel AAV capsids tailored to meet disease-specific transduction profiles. The collaboration will leverage Capsigen’s capsid engineering expertise and Biogen’s discovery, development, manufacturing, and commercialization capabilities with the goal to accelerate delivery of gene therapies to patients in need. Under the terms of the agreement, Capsigen will apply its vector engineering approaches to develop novel capsids designed to meet highly customized, disease-specific transduction profiles. Biogen will receive an exclusive license under Capsigen’s proprietary technology for an undisclosed number of CNS and neuromuscular disease targets. Capsigen will receive a $15 million upfront payment and is eligible to receive up to $42 million in potential research milestones and up to an additional $1.25 billion in potential development and commercial payments should the collaboration programs achieve certain developmental milestones and sales thresholds. Capsigen is also eligible to receive royalties on future net sales of products that incorporate capsids resulting from the collaboration.

The Wilson Sonsini Goodrich & Rosati team that advised Capsigen on IP matters related to the collaboration included Matthew Bresnahan and Brett Zirkle.

For more information, please see Capsigen’s press release.